Bolt Biotherapeutics and Toray Team Up to Target Caprin-1 for Cancer Treatment

Bolt Biotherapeutics, Inc. has unveiled its collaboration with Toray Industries, Inc. to develop a promising cancer therapy. The focus is on Caprin-1, a novel cancer target discovered by Toray that is expressed on the surface of most solid tumors. Through their partnership, Toray is supplying its proprietary monoclonal antibody, TRK-950, while Bolt contributes its Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) technology. Together, they aim to create a treatment that could benefit patients with a range of solid tumor types. The companies will jointly commercialize this promising ISAC product candidate under their existing Joint Development and License Agreement.

Caprin-1 has been identified as a significant tumor-specific antigen, playing a key role in tumor growth and metastasis. This collaboration dates back to 2002, when Dr. Fumiyoshi Okano of Toray and Dr. Ed Engleman of Bolt first began working together in cancer immunotherapy research at Stanford University. Their long-standing partnership laid the groundwork for the creation of TRK-950 and the decision to merge their respective technologies for an innovative cancer treatment. Both companies are committed to advancing oncology therapies that offer patients new hope when current treatments are insufficient.